Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis

Am J Hematol. 2019 Mar;94(3):E68-E70. doi: 10.1002/ajh.25372. Epub 2018 Dec 18.

Authors

Cynthia L Gong¹, Ann L Studdert¹, Michaela Liedtke²

Affiliations

¹ Stanford Center for High Value Care, Stanford, California.
² Stanford Cancer Institute, Stanford University Medical Center, Stanford, California.

PMID: 30536952
DOI: 10.1002/ajh.25372

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / economics*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / economics*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cost-Benefit Analysis
Dexamethasone / economics*
Dexamethasone / therapeutic use
Health Care Costs
Humans
Multiple Myeloma / drug therapy
Multiple Myeloma / economics*
Multiple Myeloma / mortality
Quality of Life
Quality-Adjusted Life Years
Recurrence
Survival Analysis
Thalidomide / analogs & derivatives*
Thalidomide / economics
Thalidomide / therapeutic use

Substances

Antibodies, Monoclonal
daratumumab
Thalidomide
Dexamethasone
pomalidomide